Company news

Guardant Health, Inc. news in 2021

Guardant Health, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer

December 16, 2021

Guardant Health Reports Third Quarter 2021 Financial Results

November 3, 2021

Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom

November 2, 2021

Guardant Health Appoints Myrtle Potter to Its Board of Directors

October 19, 2021

Guardant Health to Report Third Quarter Financial Results on November 4, 2021

October 7, 2021

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers

October 4, 2021

Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors

August 4, 2021

Guardant Health to Report Second Quarter Financial Results on August 5, 2021

July 12, 2021

Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling

June 21, 2021

CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

June 17, 2021

Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer

June 7, 2021

Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer

May 27, 2021

Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

May 20, 2021

Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers

May 18, 2021

Guardant Health Reports First Quarter 2021 Financial Results

May 5, 2021

Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer

May 2, 2021

Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity

April 29, 2021

Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer

April 26, 2021

Guardant Health to Report First Quarter Financial Results on May 6, 2021

April 11, 2021

Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer

March 31, 2021

Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test

March 29, 2021

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

March 23, 2021

Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

March 1, 2021

Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021

February 23, 2021

Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer

February 15, 2021

Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 3, 2021

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe

January 17, 2021

Calls in 2021

Decks in 2021